These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 21743305)
21. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412 [TBL] [Abstract][Full Text] [Related]
22. Regulation and splicing of scavenger receptor class B type I in human macrophages and atherosclerotic plaques. Svensson PA; Englund MC; Snäckestrand MS; Hägg DA; Ohlsson BG; Stemme V; Mattsson-Hulten L; Thelle DS; Fagerberg B; Wiklund O; Carlsson LM; Carlsson B BMC Cardiovasc Disord; 2005 Aug; 5():25. PubMed ID: 16122381 [TBL] [Abstract][Full Text] [Related]
29. [Nephrotic hyperlipidemia and its clinical significance]. Neverov NI; Srinivas KV Ter Arkh; 1990; 62(6):150-3. PubMed ID: 2218917 [No Abstract] [Full Text] [Related]
30. [Disorders of lipid metabolism (presentation of 3 cases of hyperlipemia). Fredrickson's Type II (hyperbetalipoproteinemia)]. Riopérez Carmena E; Teigell Cea L; Franco Manera R Rev Clin Esp; 1971 Aug; 122(4):347-52. PubMed ID: 5161132 [No Abstract] [Full Text] [Related]
31. Bibliography. Current world literature. Hyperlipidaemia and cardiovascular disease. Curr Opin Lipidol; 2002 Aug; 13(4):421-35. PubMed ID: 12180430 [No Abstract] [Full Text] [Related]
32. C-reactive protein: binding to lipids and lipoproteins. Pepys MB; Rowe IF; Baltz ML Int Rev Exp Pathol; 1985; 27():83-111. PubMed ID: 3915746 [No Abstract] [Full Text] [Related]
33. Functional validation of new pathways in lipoprotein metabolism identified by human genetics. Bauer RC; Stylianou IM; Rader DJ Curr Opin Lipidol; 2011 Apr; 22(2):123-8. PubMed ID: 21311327 [TBL] [Abstract][Full Text] [Related]
34. Hyperlipidemia and cardiovascular disease. Le NA Curr Opin Lipidol; 2006 Dec; 17(6):702-4. PubMed ID: 17095916 [No Abstract] [Full Text] [Related]
35. The lipoprotein apoproteins. Their role in normal lipid transport and dyslipoproteinemia. Levy RI; Eisenberg S Ann Biol Clin (Paris); 1974; 32(1):1-8. PubMed ID: 4366057 [No Abstract] [Full Text] [Related]
36. [The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis]. Piskun RP; Pentiuk AA; Serkova VK; Polesia TL; Savitskaia EA Eksp Klin Farmakol; 1997; 60(2):78-85. PubMed ID: 9206580 [TBL] [Abstract][Full Text] [Related]
37. Bile acid metabolism in hyperlipoproteinaemia. Hellström K; Einarsson K Clin Gastroenterol; 1977 Jan; 6(1):103-28. PubMed ID: 196796 [No Abstract] [Full Text] [Related]
38. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Mäkinen PI; Lappalainen JP; Heinonen SE; Leppänen P; Lähteenvuo MT; Aarnio JV; Heikkilä J; Turunen MP; Ylä-Herttuala S Cardiovasc Res; 2010 Dec; 88(3):530-8. PubMed ID: 20634212 [TBL] [Abstract][Full Text] [Related]